Zinc Chloride
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Zinc Chloride
- Zinc Chloride: From an Unrecorded Original Indication to Severe Nonproliferative Diabetic Retinopathy
Zinc Chloride: From an Unrecorded Original Indication to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Zinc chloride (DrugBank DB14533) has no recorded original indication or mechanism-of-action data in this evidence pack, and it is not currently marketed in South Africa. The TxGNN model predicts a possible role in severe nonproliferative diabetic retinopathy, but this prediction is currently supported by 0 clinical trials and 0 publications — it is an algorithmic signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record (no approved South African product, no DrugBank indication data) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for zinc chloride is not available in this evidence pack, and no original indication is on record — this drug does not have a South African market presence to anchor a “known efficacy” comparison. The prediction for severe nonproliferative diabetic retinopathy therefore rests entirely on the TxGNN knowledge-graph score (99.34%), with no corroborating clinical or literature evidence.
There is a theoretical rationale worth noting: zinc ions are a cofactor for antioxidant enzymes (e.g., Cu/Zn-superoxide dismutase) and have been studied in relation to oxidative stress and angiogenesis pathways, both of which are relevant to diabetic retinal disease. However, this link is speculative — it does not appear in any trial or publication captured for this candidate, and it should be treated as a hypothesis rather than supporting evidence.
Because both the original-indication anchor and the mechanistic pathway are unverified, this candidate sits at the earliest possible stage of the repurposing pipeline (decision stage S0) and cannot be meaningfully differentiated from a generic high-scoring model output at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Zinc chloride has no SAHPRA-registered products and is not currently marketed in South Africa (0 licences on record).
Other Predicted Indications (For Reference)
TxGNN also ranked two additional indications for zinc chloride, one of which has meaningfully stronger evidence than the lead candidate above:
| Rank | Disease | TxGNN Score | Evidence Level | Note |
|---|---|---|---|---|
| 2 | Sjögren syndrome | 99.18% | L5 | No trials, no literature — algorithmic prediction only |
| 3 | Dry eye syndrome | 99.18% | L2 | 2 completed trials (Phase 2 and Phase 4) using zinc-hyaluronate / zinc-containing formulations, not free zinc chloride — indirect support only |
For dry eye syndrome, NCT02951910 (Phase 4, completed, n=20) and NCT01541891 (Phase 2, completed, n=30) both evaluated zinc-containing ophthalmic formulations for ocular surface symptoms. These are compound preparations rather than zinc chloride alone, so the evidence is indirect, but this candidate is markedly better supported than the lead indication above and may warrant separate evaluation.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported by a TxGNN score alone (L5, decision stage S0) — there is no original indication, no mechanism-of-action data, no clinical trial, and no literature evidence linking zinc chloride to severe nonproliferative diabetic retinopathy. The drug is also not marketed in South Africa, so there is no existing safety or usage data to draw on locally.
To proceed, the following is needed:
- Confirmed mechanism-of-action data for zinc chloride (DrugBank/pharmacology reference)
- Preclinical or mechanistic studies directly linking zinc chloride to diabetic retinopathy pathways
- At least one clinical trial or observational study specific to this indication
- SAHPRA-approved Professional Information (PI), since no South African registration currently exists
- If pursuing the better-evidenced dry eye syndrome signal instead, confirmation of whether zinc chloride alone (vs. zinc-hyaluronate complexes) shows comparable activity
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.